The Africa Clinical Research Network (ACRN) has started its first clinical trial using Oracle's cloud-based safety and analytics solutions to study pre-eclampsia in African women. The PROTECT-Africa trial, running in Zimbabwe, Rwanda, and Tanzania, aims to validate biomarkers that predict severe pregnancy complications, recruiting over 1,100 participants. This initiative addresses the low representation of Africa in global clinical trials and seeks to build a sustainable research ecosystem across 14 African countries. By leveraging Oracle's technology, ACRN aims to enhance trial efficiency, patient safety, and accelerate access to relevant medical innovations for African populations.
Micron Technology's stock has surged over 760% in a year, driven by AI demand pushing memory margins to a peak 74%, but this level is unsustainable and risks a downturn. Meanwhile, Oracle reported a record fiscal Q4 with a massive backlog of $638 bil...
Oracle's stock fell 12% after earnings, but this pullback is seen as healthy following an 80% rally driven by positive sentiment. The company continues to show accelerating revenue growth, particularly in its Infrastructure-as-a-Service (IaaS) segmen...
Oracle's cloud infrastructure revenue is growing rapidly, with multi-cloud partnerships and outcome-based pricing driving Record Performance Orders (RPOs) to $638 billion, up 362.3% year-over-year. The company manages risks through disciplined capita...
The Centre for Addiction and Mental Health (CAMH), Canada's largest mental health teaching hospital, is implementing Oracle Fusion Cloud Applications to unify its clinical and administrative systems. This move aims to improve operational visibility, ...
Oracle has been upgraded to a Strong Buy due to its impressive AI-driven growth and strong cloud business momentum. The company reported stellar earnings with 47% growth in cloud revenue and a 93% increase in cloud infrastructure revenue, although it...
